Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company developing seven clinical and pre-clinical brain disease programs, has scheduled its third quarter 2024 financial results conference call and webcast for Tuesday, November 12, 2024, at 8:00 a.m. ET. The event will include a business update and will be available on the company's website, with a replay archived for up to 30 days. Participants are encouraged to register at least 10 minutes before the call.
Neumora Therapeutics (Nasdaq: NMRA), un'azienda biofarmaceutica in fase clinica che sta sviluppando sette programmi clinici e pre-clinici per malattie cerebrali, ha programmato la sua conferenza sui risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024, alle 8:00 ora EST. L'evento includerà un aggiornamento aziendale e sarà disponibile sul sito web dell'azienda, con una registrazione archiviata per un massimo di 30 giorni. Si incoraggiano i partecipanti a registrarsi almeno 10 minuti prima della chiamata.
Neumora Therapeutics (Nasdaq: NMRA), una empresa biofarmacéutica en etapa clínica que desarrolla siete programas clínicos y preclínicos para enfermedades cerebrales, ha programado su llamada de conferencia sobre resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024, a las 8:00 a.m. ET. El evento incluirá una actualización empresarial y estará disponible en el sitio web de la compañía, con una repetición archivada durante un máximo de 30 días. Se anima a los participantes a registrarse al menos 10 minutos antes de la llamada.
Neumora Therapeutics (Nasdaq: NMRA)는 일곱 가지 임상 및 비임상 뇌 질환 프로그램을 개발하고 있는 임상 단계의 바이오제약 회사로, 2024년 3분기 재무 결과에 대한 컨퍼런스 콜 및 웹캐스트를 2024년 11월 12일 화요일 오전 8:00 (동부 표준시)에 예정했습니다. 이 이벤트에는 비즈니스 업데이트가 포함되며, 회사 웹사이트에서 제공되며, 최대 30일 동안 다시 들을 수 있도록 기록됩니다. 참가자들은 콜 시작 최소 10분 전에 등록하는 것이 권장됩니다.
Neumora Therapeutics (Nasdaq: NMRA), une société biopharmaceutique en phase clinique développant sept programmes cliniques et précliniques pour des maladies du cerveau, a programmé sa conférence sur les résultats financiers du troisième trimestre 2024 pour mardi 12 novembre 2024, à 8h00 EST. L'événement inclura une mise à jour sur l'entreprise et sera disponible sur le site web de la société, avec une rediffusion accessible pendant 30 jours. Les participants sont encouragés à s'inscrire au moins 10 minutes avant l'appel.
Neumora Therapeutics (Nasdaq: NMRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sieben klinische und präklinische Programme für Hirnerkrankungen entwickelt, hat seine Konferenz zu den finanziellen Ergebnissen des dritten Quartals 2024 für Dienstag, den 12. November 2024, um 8:00 Uhr ET angesetzt. Die Veranstaltung umfasst ein Unternehmensupdate und wird auf der Website des Unternehmens verfügbar sein, mit einer Aufzeichnung, die bis zu 30 Tage lang archiviert wird. Teilnehmer werden ermutigt, sich mindestens 10 Minuten vor dem Anruf anzumelden.
- None.
- None.
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 12, 2024 to report its third quarter 2024 financial results and provide a business update.
A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora Contact:
Helen Rubinstein
315-382-3979
Helen.Rubinstein@neumoratx.com
FAQ
When will Neumora Therapeutics (NMRA) report Q3 2024 earnings?
How can I access Neumora Therapeutics (NMRA) Q3 2024 earnings call?
How long will Neumora Therapeutics (NMRA) Q3 2024 earnings call replay be available?
